David R.  McAvoy net worth and biography

David McAvoy Biography and Net Worth

General Counsel of Brickell Biotech
David McAvoy joins Brickell Biotech as General Counsel. Prior to this, Dave served as General Counsel, Vice President and Chief Compliance Officer for the nuclear medicine and oncology biotech Endocyte, Inc., helping it to be acquired successfully by Novartis AG for $2.1 billion in December 2018.
Before Endocyte, Mr. McAvoy was at Eli Lilly and Company for 27 years including as General Counsel of Lilly Emerging Markets – at the time, a $3 billion company division – and most recently there in an executive management business role running strategic alliances for the food animal production group at Lilly’s former Elanco Animal Health subsidiary, now spun off. Also at Lilly, Mr. McAvoy was lead counsel for several iconic medicines, including Prozac® for depression, Gemzar® for pancreatic and lung cancers, and ReoPro®, one of the first interventional cardiology agents. While there he partnered with FDA to create important policy precedents in orphan drug, direct-to-consumer advertising of pharmaceuticals, and clinical trial transparency that influence the industry favorably today.

Mr. McAvoy earned a J.D. and Master of Science in Environmental Science with highest honors from Indiana University, and a B.A. in political science from the University of Notre Dame. He serves on the Board of Directors for The Villages of Indiana, Inc., championing families for abandoned and abused children.

What is David R. McAvoy's net worth?

The estimated net worth of David R. McAvoy is at least $0.00 as of May 17th, 2021. Mr. McAvoy owns 110,755 shares of Brickell Biotech stock worth more than $0 as of March 28th. This net worth approximation does not reflect any other investments that Mr. McAvoy may own. Learn More about David R. McAvoy's net worth.

How do I contact David R. McAvoy?

The corporate mailing address for Mr. McAvoy and other Brickell Biotech executives is 5777 CENTRAL AVENUE SUITE 102, BOULDER CO, 80301. Brickell Biotech can also be reached via phone at (720) 505-4755 and via email at [email protected]. Learn More on David R. McAvoy's contact information.

Has David R. McAvoy been buying or selling shares of Brickell Biotech?

David R. McAvoy has not been actively trading shares of Brickell Biotech during the last ninety days. Most recently, on Friday, July 23rd, David R. Mcavoy bought 18,124 shares of Brickell Biotech stock. The stock was acquired at an average cost of $0.67 per share, with a total value of $12,143.08. Following the completion of the transaction, the general counsel now directly owns 128,879 shares of the company's stock, valued at $86,348.93. Learn More on David R. McAvoy's trading history.

Who are Brickell Biotech's active insiders?

Brickell Biotech's insider roster includes Robert Brown (CEO), Deepak Chadha (Insider), Reginald Hardy (Chairman), David McAvoy (General Counsel), and Andrew Sklawer (COO). Learn More on Brickell Biotech's active insiders.

David R. McAvoy Insider Trading History at Brickell Biotech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/23/2021Buy18,124$0.67$12,143.08128,879View SEC Filing Icon  
5/17/2021Buy18,622$0.80$14,897.60110,755View SEC Filing Icon  
9/18/2020Buy22,526$0.83$18,696.5875,883View SEC Filing Icon  
See Full Table

David R. McAvoy Buying and Selling Activity at Brickell Biotech

This chart shows David R Mcavoy's buying and selling at Brickell Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Brickell Biotech Company Overview

Brickell Biotech logo
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.86
Low: $0.77
High: $0.93

2 Week Range

Now: N/A

Volume

31,300 shs

Average Volume

206,730 shs

Market Capitalization

$6.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02